Business context and reporting period
The supplied filing is Aziyo Biologics, Inc.’s Form 10-K for the fiscal year ended December 31, 2022, filed March 23, 2023; it is not a standalone fourth-quarter report. The filing identifies the company as Aziyo Biologics (Nasdaq: AZYO), not ELUTIA INC., as stated in the request metadata. Investors should confirm the intended issuer.
Aziyo is a commercial-stage regenerative medicine company selling tissue-based products across device protection, women’s health, orthobiologics and cardiovascular markets. It reports four corresponding segments and uses direct sales, commercial partners and independent agents.
Financial performance and position
| Metric | 2022 | 2021 |
|---|---|---|
| Net sales | $49.2 million | $47.4 million |
| Gross profit / margin | $19.2 million / 39.1% | $19.0 million / 40.1% |
| Operating loss | $31.7 million | $23.0 million |
| Net loss | $32.9 million | $24.8 million |
| Net loss per share, basic and diluted | $2.38 | $2.38 |
| Cash used in operating activities | $21.4 million | $15.4 million |
| Cash used in investing activities | $0.5 million | $0.4 million |
| Cash provided by financing activities | $8.5 million | $6.7 million |
- Cash was $17.0 million at December 31, 2022, down from $30.4 million a year earlier. The company reported a $13.4 million net decrease in cash and restricted cash.
- Current assets were $50.7 million and current liabilities $42.6 million. Stockholders’ equity was negative $5.0 million, compared with positive $13.5 million in 2021.
- Long-term debt was $24.3 million, net of unamortized discount and deferred financing costs. The new SWK facility had $25.3 million principal outstanding before those deductions; its weighted-average interest rate was 12.6% from August through year-end.
- The Ligand Revenue Interest Obligation was $14.9 million at year-end ($9.0 million current and $5.9 million long-term). It requires 5% of specified product sales, subject to $2.75 million annual minimum payments and sales-based milestones.
Material changes versus 2021
- Sales grew 3.8% overall. Device Protection increased 15.1% to $9.1 million; Women’s Health rose 48.1% to $7.5 million; Orthobiologics fell 5.9% to $25.3 million; Cardiovascular declined 3.0% to $7.3 million.
- Orthobiologics sales declined partly because Medtronic sales ended after the FiberCel recall. Excluding $4.9 million of 2021 Medtronic sales, orthobiologics sales increased $3.3 million, principally from contract manufacturing customers.
- Gross margin fell 1.0 percentage point to 39.1%; excluding acquired-intangible amortization, it declined to 46.0% from 47.3%. The filing cites lower-margin contract manufacturing mix in Orthobiologics and operational inefficiencies in Device Protection.
- Operating expenses rose 21.2% to $51.0 million, including FiberCel litigation costs of $5.2 million versus $0.3 million. General and administrative expense increased 21.5%, partly due to corporate legal matters and the CEO transition.
- In August 2022, the company refinanced prior MidCap facilities with a $25 million secured SWK term loan, drawing $21 million initially and another $4 million in December. It also raised approximately $10.2 million net through a December 2022 public offering.
- Other income included a $5.0 million gain from revaluation of the Ligand obligation. This non-operating, estimate-driven gain reduced reported net loss relative to what it otherwise would have been.
Outlook, commentary and key risks
- Going concern: Management and the auditor report substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the financial statements. The company expects continued operating losses and cash outflows and says existing cash, expected sales and potential financing may not be sufficient for the next 12 months. Management may seek equity or debt financing, restructure the Ligand obligation, or pursue asset sales or other transactions; success is uncertain.
- CanGaroo RM: The company submitted a 510(k) application in April 2022. In March 2023, FDA issued a Not Substantially Equivalent determination and requested additional drug-testing work, including changes to an in-vitro release assay. Aziyo said it intended to address the questions and continue working with FDA; timing and clearance are uncertain.
- FiberCel litigation: Following recall of one donor lot in 2021 after tuberculosis infections were identified, the company reported 26 cases settled for approximately $7.3 million, of which 11 settlements totaling $3.6 million had been paid by year-end. It recorded a total liability of $17.4 million and insurance/other recovery receivables of $13.8 million. It also reported 81 matters without settlements and 47 additional claims that had not yet resulted in lawsuits. The company could not estimate any loss above the recorded liability; it was pursuing at least $3.8 million in additional recoveries that were not recognized.
- Debt and cash requirements: The SWK loan is secured by company assets, carries variable SOFR-based interest, has financial covenants and matures in 2027. Principal amortization is scheduled to begin in November 2024, subject to possible extension. The company reported covenant compliance at year-end, but future compliance is not assured. The Ligand agreement’s first $5.0 million sales milestone was forecast by management to become payable in mid-2023.
- Other risks: The company depends on commercial partners and contract manufacturing customers, has a sole porcine-tissue supplier for key products, and relies on donated human tissue. Product safety, regulatory, reimbursement, competition, inventory, clinical evidence and financing risks are significant. The filing notes that more than 98% of 2022 net sales came from the United States.
- Management and operations: The CEO changed in 2022. In March 2023, the Chief Commercial Officer’s position was eliminated as part of a headcount reduction; he was to provide transition assistance through October 8, 2023. The company provided no quantified sales or earnings guidance in the supplied filing text.
Important facts for investors to verify
- Confirm the issuer: the filing is for Aziyo Biologics, Inc. (AZYO), despite the ELUTIA INC. request metadata.
- Review the auditor’s going-concern paragraph and management’s liquidity plans, including subsequent financing, cash runway and any developments after March 23, 2023.
- Check the status and cost of addressing FDA’s CanGaroo RM questions, and whether or when a revised submission or clearance occurred.
- Track FiberCel settlements, defense expenses, insurance and indemnity recoveries, and changes to the $17.4 million liability and $13.8 million receivable.
- Verify the Ligand milestone payment timing and the terms and covenant headroom of the SWK debt, including variable-rate interest and future amortization.
- Assess whether sales growth, segment margins and customer concentration can improve enough to reduce operating cash burn; 2022 losses widened despite modest revenue growth.